EconPapers    
Economics at your fingertips  
 

Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis

Fredrik Salvesen Haukaas (), Trude Margrete Arnesen, Brita Askeland Winje and Eline Aas
Additional contact information
Fredrik Salvesen Haukaas: Norwegian Institute of Public Health
Trude Margrete Arnesen: Norwegian Institute of Public Health
Brita Askeland Winje: Norwegian Institute of Public Health

The European Journal of Health Economics, 2017, vol. 18, issue 4, No 2, 405-415

Abstract: Abstract The incidence of tuberculosis (TB) disease has increased in Norway since the mid-1990s. Immigrants are screened, and some are treated, for latent TB infection (LTBI) to prevent TB disease (reactivation). In this study, we estimated the costs of both treating and screening for LTBI and TB disease, which has not been done previously in Norway. We developed a model to indicate the cost-effectiveness of four different screening algorithms for LTBI using avoided TB disease cases as the health outcome. Further, we calculated the expected value of perfect information (EVPI), and indicated areas of LTBI screening that could be changed to improve cost-effectiveness. The costs of treating LTBI and TB disease were estimated to be €1938 and €15,489 per case, respectively. The model evaluates four algorithms, and suggests three cost-effective algorithms depending on the cost-effectiveness threshold. Screening all immigrants with interferon-gamma release assays (IGRA) requires the highest threshold (€28,400), followed by the algorithms “IGRA on immigrants with risk factors” and “no LTBI screening.” EVPI is approximately €5 per screened immigrant. The costs for a cohort of 20,000 immigrants followed through 10 years range from €12.2 million for the algorithm “screening and treatment for TB disease but no LTBI screening,” to €14 million for “screening all immigrants for both TB disease and LTBI with IGRA.” The results suggest that the cost of TB disease screening and treatment is the largest contributor to total costs, while LTBI screening and treatment costs are relatively small. Increasing the proportion of IGRA-positive immigrants who are treated decreases the costs per avoided case substantially.

Keywords: Latent tuberculosis; Cost-effectiveness analysis; CEA; Screening; Immigrants; Expected value of perfect information; EVPI; Economic evaluation; IGRA; TST; Tuberculin skin test; Interferon gamma release assay; Norway; Tuberculosis; I110; I120; I180 (search for similar items in EconPapers)
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-016-0779-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:18:y:2017:i:4:d:10.1007_s10198-016-0779-0

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-016-0779-0

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2024-10-11
Handle: RePEc:spr:eujhec:v:18:y:2017:i:4:d:10.1007_s10198-016-0779-0